BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]
, 2015 Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim +3 more
core +4 more sources
International Journal of Hyperthermia, 2021 Purpose We aimed to determine the effects and possible mechanisms of hyperthermic intraperitoneal chemotherapy (HIPEC) in targeting ovarian cancer stem-like cells (CSCs).
Chao-Chih Wu +2 more
doaj +1 more source
Peritoneal Canceromatosis in Malignant Tumors of Various Localizations. Achievements and Prospects
Креативная хирургия и онкология, 2021 Peritoneal carcinomatosis is viewed by many experts as a terminal illness with an unfavourable course and prognosis. Existing therapies are controversial and exhibit ambiguous efficacy.
Sh. Kh. Gantsev +3 more
doaj +1 more source
Gynecologic Oncology Reports, 2020 Sertoli Leydig cell tumor (SLCT) is a rare sex-cord stromal tumor of the ovary that generally has a benign course. Here, we report an unusual case of recurrent, metastatic SLCT and its unique management with a combination of cytoreductive surgery ...
Nicholas K. Larsen +4 more
doaj +1 more source
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: our initial experience of implementation and detailed technique [PDF]
Ķazaķstannyṇ Klinikalyķ Medicinasy, 2019 Objective: The aim of this study is to present our initial implementation experience in peritoneal carcinomatosis treatment and the technical details of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the light of current ...
Talgat Uskenbayev +4 more
doaj +1 more source
Mechanistic Insights on Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Cancers, 2023 Simple Summary Advanced ovarian cancer is the leading cause of gynecological death with a high rate of reoccurrence indicating the critical need for improved therapeutics. Hyperthermic intraperitoneal chemotherapy (HIPEC) treatment for ovarian cancer has
Olivia G Huffman +4 more
semanticscholar +1 more source
Temperature management during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Frontiers in Oncology, 2023 In addition to attaining complete or near complete cytoreduction, the instillation of select heated chemotherapeutic agents into the abdominal cavity has offered a chance for cure or longer survival inpatients with peritoneal surface malignancies.
M. Ramirez +4 more
semanticscholar +1 more source
Is Cytoreductive Surgery Possible in Cervical Cancer Peritoneal Carcinomatosis?
Clinical Medicine Insights: Oncology, 2021 Background: The number of cases of cervical cancer with recurrence and peritoneal carcinomatosis is limited. In our study, we aimed to present the results of cytoreductive surgery hyperthermic intraperitoneal chemotherapy treatment and its 3-year early ...
Ozgul Duzgun, Murat Kalin
doaj +1 more source
The effect of intraoperative abdominal pressure on blood platinum levels and early complications during hyperthermic intraperitoneal chemotherapy. [PDF]
BMC SurgKulturoglu MO +6 more
europepmc +3 more sources
Initial Experience With Hyperthermic Intraperitoneal Chemotherapy [PDF]
Archives of Surgery, 2012 Until 2004, we treated peritoneal carcinomatosis with cytoreductive surgery accompanied by perioperative systemic chemotherapy. From October 2004, we decided to initiate a hyperthermic intraperitoneal chemotherapy (HIPEC) program for this condition.To determine the effect of HIPEC on postoperative outcomes at a single institution performing a high ...
Olivier, Turrini +6 more
openaire +2 more sources